ArticleOncoimmunology2020
Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features.Cancer immunology, immunotherapy : CII · 2026Pooled it
- Toward the benefit and value of immune treatment beyond progression in lung cancer? Insights from a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Utility of iRECIST for evaluating treatment efficacy in patients receiving immune checkpoint inhibitors.Journal of gynecologic oncology · 2026Article
- Continuing immune checkpoint inhibitors after pseudoprogression improves survival in lung cancer patients: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.Korean journal of radiology · 2025Review
- Pseudoprogression of pleural effusion in lung cancer treated with immunotherapy: a case report.Translational lung cancer research · 2025Article
- Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis.Journal of clinical medicine · 2025Review
- Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors.Journal of neuro-oncology · 2025Article
- Hepatocellular Carcinoma Presenting with Pseudoprogression in a Patient Receiving Atezolizumab Plus Bevacizumab Combination Therapy.Internal medicine (Tokyo, Japan) · 2025Article
- Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.Frontiers in immunology · 2025Observational
- Development and validation of a novel nomogram for predicting outcomes in advanced lung cancer patients treated beyond progression with immune checkpoint inhibitors.Frontiers in immunology · 2025Article
- Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.Translational lung cancer research · 2024Article
- Repeated dynamic [European journal of nuclear medicine and molecular imaging · 2024Observational
- A novel nomogram for predicting the prognosis of hepatocellular carcinoma patients following immune checkpoint inhibitors treatment beyond progression: a single center study based on Chinese population.Hepatobiliary surgery and nutrition · 2024Article
- The NSCLC immunotherapy response predicted by tumor-infiltrating T cells via a non-invasive radiomic approach.Frontiers in immunology · 2024Article
- Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression.Frontiers in immunology · 2023Article
- A novel [Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICI) have become an important treatment option for non-small cell lung cancer (NSCLC). We aimed to evaluate the clinical impact of pseudoprogression (PsP) and treatment beyond RECIST1.1-defined progressive disease (TBP) on outcome in NSCLC patients treated with ICI. Methods: NSCLC patients treated with ICI between Mar 2016 and July 2018 were recruited in a consecutive manner. Response was assessed every 8-12 weeks using RECIST1.1 and iRECIST. Based on iRECIST, PsP was defined as progressive disease (PD) on RECIST1.1 subsequently reset to non-PD categories. Using log-rank test, progression-free survival (PFS) was compared between patients with and without PsP, and overall survival (OS) was compared between patients treated with and without TBP. The impact of TBP on OS was evaluated through multivariate Cox proportional hazard models. Results: Of the 189 patients, seven (3.7%) experienced PsP which mostly occurred approximately 3 months after baseline. The median PFS was significantly longer in patients with PsP (not reached) than those without PsP (3.8 months, Conclusion: PsP occurred in 3.7% of NSCLC patients under ICI treatment. Based on iRECIST scheme, PsP and TBP may be associated with survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.